Vertex Pharmaceuticals Total Cost of Revenue decreased by 15.7% to $392.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.2%, from $363.00M to $392.80M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 16.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $228.00M | $236.50M | $247.40M | $245.80M | $261.80M | $289.40M | $283.30M | $266.90M | $308.60M | $318.70M | $368.00M | $342.60M | $371.90M | $392.60M | $423.40M | $363.00M | $407.50M | $414.80M | $466.00M | $392.80M |
| QoQ Change | — | +3.7% | +4.6% | -0.6% | +6.5% | +10.5% | -2.1% | -5.8% | +15.6% | +3.3% | +15.5% | -6.9% | +8.6% | +5.6% | +7.8% | -14.3% | +12.3% | +1.8% | +12.3% | -15.7% |
| YoY Change | — | — | — | — | +14.8% | +22.4% | +14.5% | +8.6% | +17.9% | +10.1% | +29.9% | +28.4% | +20.5% | +23.2% | +15.1% | +6.0% | +9.6% | +5.7% | +10.1% | +8.2% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Product revenues, net | $130.60M | $140.50M | $139.60M | $190.80M | $160.20M |
| Royalty | $232.40M | — | — | — | — |
| Total | $363.00M | $407.50M | $414.80M | $466.00M | $392.80M |